Why the study?
Does aerosolized ALN-RSV01 improve symptoms and prevent bronchiolitis obliterans syndrome in lung transplant recipients with RSV infection?
Population
24 lung transplant (LTX) recipients with respiratory syncytial virus (RSV) respiratory tract infection.
Comparison
Aerosolized ALN-RSV01 administered daily for 3… vs Placebo administered daily for 3 days, in…
Design
RCT, Randomized, stratified by ribavirin use, Double-blind, placebo-controlled
Follow-up
90 days
Authors
Loading...
Supports ALN-RSV01 to reduce BOS in RSV-infected lung transplant recipients; extends RNAi antiviral evidence to post-transplant settings.
Does aerosolized ALN-RSV01 improve symptoms and prevent bronchiolitis obliterans syndrome in lung transplant recipients with RSV infection?
Aerosolized ALN-RSV01 appears safe and may reduce the incidence of bronchiolitis obliterans syndrome in lung transplant patients with RSV infection.
Zamora et al. (2010) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: